JP2001516338A5 - - Google Patents

Download PDF

Info

Publication number
JP2001516338A5
JP2001516338A5 JP1998515702A JP51570298A JP2001516338A5 JP 2001516338 A5 JP2001516338 A5 JP 2001516338A5 JP 1998515702 A JP1998515702 A JP 1998515702A JP 51570298 A JP51570298 A JP 51570298A JP 2001516338 A5 JP2001516338 A5 JP 2001516338A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998515702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/016348 external-priority patent/WO1998013340A1/en
Publication of JP2001516338A publication Critical patent/JP2001516338A/ja
Publication of JP2001516338A5 publication Critical patent/JP2001516338A5/ja
Withdrawn legal-status Critical Current

Links

JP51570298A 1996-09-27 1997-09-19 マトリックスメタロプロテイナーゼ・インヒビターとしてのβ―スルホニルヒドロキサム酸 Withdrawn JP2001516338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
US60/026,848 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (2)

Publication Number Publication Date
JP2001516338A JP2001516338A (ja) 2001-09-25
JP2001516338A5 true JP2001516338A5 (enExample) 2005-05-12

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51570298A Withdrawn JP2001516338A (ja) 1996-09-27 1997-09-19 マトリックスメタロプロテイナーゼ・インヒビターとしてのβ―スルホニルヒドロキサム酸

Country Status (21)

Country Link
US (2) US6235928B1 (enExample)
EP (1) EP0929519B1 (enExample)
JP (1) JP2001516338A (enExample)
KR (1) KR20000048639A (enExample)
CN (1) CN1158254C (enExample)
AT (1) ATE289590T1 (enExample)
AU (1) AU726799B2 (enExample)
BR (1) BR9712134A (enExample)
CA (1) CA2266368A1 (enExample)
CZ (1) CZ92399A3 (enExample)
DE (1) DE69732571T2 (enExample)
EA (1) EA001460B1 (enExample)
ES (1) ES2236829T3 (enExample)
HU (1) HUP0000145A3 (enExample)
ID (1) ID21897A (enExample)
IL (1) IL128900A0 (enExample)
NO (1) NO312893B1 (enExample)
NZ (1) NZ334729A (enExample)
PL (1) PL332509A1 (enExample)
UA (1) UA48262C2 (enExample)
WO (1) WO1998013340A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CZ297278B6 (cs) * 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
ID21897A (id) 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
PT960096E (pt) 1997-01-22 2005-08-31 Aventis Pharma Inc Acidos beta-tiocarboxilicos substituidos
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
IL131493A (en) * 1997-03-04 2004-05-12 Monsanto Co Aromatic compounds of the hydroxamic sulfonyl alpha-deroxamic acid and their use in the preparation of drugs for the treatment of a condition associated with pathological activity of the metalloprotease matrix
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
PT1037868E (pt) * 1997-11-21 2003-06-30 Upjohn Co Derivados alfa-hidroxi amino e halo de acidos beta-sulfonil-hidroxamicos como inibidores de metaloproteinases matriciais
DE69934094T2 (de) * 1998-01-30 2007-06-06 Darwin Discovery Ltd., Slough N-hydroxyformamid-derivate
EP1357109B1 (en) 1998-06-18 2008-07-23 F. Hoffmann-La Roche Ag Process for aryl alkyl sulfide
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) * 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2632030A1 (en) 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008014199A2 (en) * 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
KR20090069318A (ko) * 2006-09-25 2009-06-30 베링거 인겔하임 인터내셔날 게엠베하 Cb2 수용체를 조절하는 화합물
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2326629B1 (en) 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
CA2737645A1 (en) * 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (en) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5525629A (en) * 1992-04-07 1996-06-11 British Bio-Technology Limited Inhibition of cytokine production
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
DK0780386T3 (da) * 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
ID21897A (id) 1996-09-27 1999-08-05 Upjohn Co Asam b-sulfonil hidroksamat sebagai bahan penghambat matriks metaloproteinase
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Similar Documents

Publication Publication Date Title
JP2000512098A5 (enExample)
JP2000507816A5 (enExample)
JP2000504898A5 (enExample)
JP2000514337A5 (enExample)
JP2000509282A5 (enExample)
JP2000511733A5 (enExample)
JP2000515363A5 (enExample)
JP2000510018A5 (enExample)
JP2000512498A5 (enExample)
JP2000513647A5 (enExample)
JP2000512231A5 (enExample)
JP2000503617A5 (enExample)
JP2000508468A5 (enExample)
JP2000507952A5 (enExample)
JP2000511407A5 (enExample)
JP2000507133A5 (enExample)
JP2000512328A5 (enExample)
JP2002509487A5 (enExample)
JP2001501458A5 (enExample)
JP2000504045A5 (enExample)
JP2000503984A5 (enExample)
JP2001502170A5 (enExample)
JP2000509404A5 (enExample)
JP2000501569A5 (enExample)
JP2000508301A5 (enExample)